POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides a source of calories and energy. Sodium chloride provides sodium and chloride ions for electrolyte balance and fluid distribution.
| Metabolism | Potassium is primarily excreted by the kidneys; dextrose is metabolized via glycolysis and oxidative phosphorylation; sodium and chloride are not metabolized but excreted in urine and sweat. |
| Excretion | Primarily renal (>90%); potassium is filtered and actively secreted in distal tubules; negligible fecal or biliary elimination. Dextrose and sodium are metabolized or renally eliminated. |
| Half-life | Potassium: 1-1.5 hours (rapid redistribution); clinical context: steady-state achieved in 24-48 hours with continuous infusion; elimination half-life prolonged in renal impairment. |
| Protein binding | Potassium: negligible (<2%); dextrose and sodium: not significantly protein bound. |
| Volume of Distribution | Potassium: 0.4-0.6 L/kg (total body water); clinical meaning: reflects distribution primarily in extracellular fluid with intracellular uptake via Na+/K+ ATPase. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (seconds to minutes) due to direct vascular administration; oral: not applicable as this is IV formulation. |
| Duration of Action | Intravenous: 2-4 hours for electrolyte correction; depends on infusion rate and underlying deficits; continuous infusion maintains steady levels. |
Intravenous infusion. Rate and volume determined by patient's fluid and electrolyte needs; typical adult maintenance: 100-200 mL/h (providing K+ 1.5-3 mEq/h).
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment. GFR 10-50 mL/min: reduce rate or volume to avoid K+ accumulation; monitor K+ closely. GFR <10 mL/min: avoid use due to risk of hyperkalemia. |
| Liver impairment | No specific dose adjustment for Child-Pugh class; monitor potassium and glucose levels due to potential for altered metabolism. |
| Pediatric use | Weight-based: 2-4 mEq/kg/day potassium, 5-10 mL/kg/h dextrose 5% (providing 0.2-0.4 g/kg/h dextrose) and 0.45% NaCl; adjust based on serum electrolytes and clinical status. |
| Geriatric use | Use with caution; monitor renal function and serum potassium. Initiate at lower infusion rates (e.g., 50-100 mL/h) and titrate based on response and electrolyte levels. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and chloride are normal constituents of breast milk; intravenous administration does not significantly alter milk levels. Dextrose and sodium chloride are also normal constituents. No specific M/P ratio available; expected to be low. Use during breastfeeding is considered compatible, but monitor maternal serum electrolytes if high doses are used. |
| Teratogenic Risk |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (not this specific concentration) are for slow intravenous infusion only and must be diluted before use to avoid fatal hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria","Addison's disease","Adynamia episodica hereditaria","Severe metabolic alkalosis","Concomitant use with potassium-sparing diuretics (unless specifically indicated)"]
| Precautions | ["Monitor serum potassium levels to avoid hyperkalemia and hypokalemia","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Not for rapid infusion or undiluted administration","Contains dextrose, caution in diabetic patients","Monitor fluid and electrolyte balance"] |
Loading safety data…
| Potassium chloride and dextrose/sodium chloride solutions are generally considered low risk for teratogenicity. No evidence of fetal harm from potassium chloride at therapeutic doses. Dextrose and sodium chloride are physiologic components. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia) can adversely affect the fetus. First trimester: No known teratogenic effect. Second/third trimester: Risk of fetal electrolyte disturbances if maternal levels are abnormal. High dextrose concentrations may cause fetal hyperglycemia and hyperinsulinemia. |
| Fetal Monitoring | Monitor maternal serum potassium, sodium, glucose, and chloride levels periodically during infusion. Assess fluid balance (input/output). In pregnancy, monitor fetal heart rate and uterine contractions during intravenous therapy. Observe for signs of fluid overload or electrolyte abnormalities in mother. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride or sodium chloride at therapeutic doses. Dextrose solutions may affect glucose metabolism but no direct fertility impact. Electrolyte imbalances (e.g., hyperkalemia) could potentially affect reproductive function, but not at standard replacement doses. |